2017-02-14T17:08:06-07:00 2016-06-30 990 2015-07-01 730580274 OKLAHOMA MEDICAL RESEARCH FOUNDATION OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen Chief Financial Officer 4052717421 2017-02-14 2015 2021-01-29 14:40:06Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 74180270 0 X www.omrf.org X 1946 OK OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 73 73 551 0 0 0 51927439 55448766 6952995 9728825 2973763 2658578 4202579 4536479 66056776 72372648 0 0 0 0 35520534 34522756 0 0 1993044 36927376 38620467 72447910 73143223 -6391134 -770575 392496683 379327594 60801464 63023022 331695219 316304572 OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 0 0 25499503 0 19959856 Arthritis & Clinical Immunology/Clinical Operations - Recognized by the National Institutes of Health as one only 10 Autoimmunity Centers of Excellence in the country, researchers in this program focus on diseases in which the body mistakenly turns the weapons of the immune system against itself. By blending laboratory research with patient studies, program leader Dr. Judith James and her colleagues have created a model for how physicians and scientists can work together to create better outcomes for people suffering from conditions such as lupus, rheumatoid arthritis and multiple sclerosis. This partnership between researchers and clinicians spurred the publication of 71 new research studies this past year, including dozens on the molecular mechanisms of lupus and one that identified 10 new genes associated with the disease. These researchers also secured a major grant to study an immune cell linked to asthma and published new findings about vision loss in MS and why autoimmune illnesses disproportionately strike women. Ultimately, says James, "The goal is to improve the lives of patients with these diseases." 4775399 0 5800521 Cardiovascular Biology Research Program - Scientists in this program concentrate their research on the blood-how it flows, how it clots and how blood vessels grow. In November, a blue-ribbon panel of independent scientific advisors from leading institutions around the country reviewed this group of cardiovascular biologists. Their conclusion? "You have a great team of researchers in this program," said Dr. Thomas Tedder, chair of the scientific advisory board and a professor of immunology at Duke University School of Medicine. "They are a dynamic, smart, interactive group." Work in this program is fundamental to understanding and treating a wide variety of diseases, and in 2016 research led down many different paths. Important studies cast new light on the development of blood vessels, cardiovascular disease in HIV, and intestinal illnesses like colitis. OMRF cardiovascular biologists also made significant progress toward the development of novel therapies for victims of traumatic injuries like gunshot wounds and motor vehicle accidents. Finally, they made a series of findings on how to prevent vascular growth. These insights could one day prove key to starving the blood supply to cancerous tumors, a mechanism that scientists will continue to explore in hopes of developing new therapies to treat various forms of cancer. "This," said scientific advisory board member Dr. Gilbert White, "is one of my models for how a research institute should be run." 3165770 0 2866572 Aging and Metabolism Research Program - With work that shares the theme of trying to improve people's healthspans-the length of time they enjoy active, productive lives-scientists in this program won major grants in 2016 to study how diabetes affects the heart and ways to fight age-related muscle loss. They also made discoveries that could lead to new therapies for osteoarthritis and novel ways to treat patients who've suffered heart attacks. The American Aging Association capped the year by honoring the work of program chair Dr. Holly Van Remmen with its highest prize for her contributions to the field of aging research. 33188298 0 7178928 Other Program Services 33188298 0 7178928 66628970 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 137 0 1 551 1 0 0 0 0 1 1 1 1 0 0 0 1 1 0 X 73 73 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 OK X X X Tim Hassen 4052717421 825 NE 13th Street Oklahoma City OK 73104 Allen Greg S Board Member 1 0 X 0 0 0 Anoatubby Bill Board member 1 0 X 0 0 0 Bell Sharon Board Member 1 0 X 0 0 0 Benbrook Bruce Board Member 1 0 X 0 0 0 Benham Lance Board Member 1 0 X 0 0 0 Boghetich Jil Board Member 1 0 X 0 0 0 Braught Barbara Board Member 1 0 X 0 0 0 Burgess Bill Board Member 1 0 X 0 0 0 Brown Randy Board Member 1 0 X 0 0 0 Burgess Ellen Board Member 1 0 X 0 0 0 Cameron Bill Board Member 1 0 X 0 0 0 Carolina Mike Board Member 1 0 X 0 0 0 Carroll Michael Board Member 1 0 X 0 0 0 Cason Len Board Member 1 0 X 0 0 0 Cawley Michael Board Member 1 0 X 0 0 0 Champlin Hiram Board Member 1 0 X 0 0 0 Collins Mark Board Member 1 0 X 0 0 0 Drake Ramsey Board Member 1 0 X 0 0 0 Duncan Walt Board Member 1 0 X 0 0 0 Eagan Claire Board Member 1 0 X 0 0 0 Edwards Carl Board Member 1 0 X 0 0 0 Evans Pat Board Member 1 0 X 0 0 0 Everest Christy Board Member 1 0 X 0 0 0 Felton Ann Board Member 1 0 X 0 0 0 Fergeson Ken Board Member 1 0 X 0 0 0 Ferree Larry Board Member 1 0 X 0 0 0 Fischer Malinda Board Member 1 0 X 0 0 0 Fretwell Barbara Board Member 1 0 X 0 0 0 Funke Mark Board Member 1 0 X 0 0 0 Gamble Gerald Board Member 1 0 X 0 0 0 Griffin John Board Member 1 0 X 0 0 0 Groendyke Virginia Board Member 1 0 X 0 0 0 Haglund Jacqui Board Member 1 0 X 0 0 0 Hall Brooks Board Member 1 0 X 0 0 0 Hargis Burns Board Member 1 0 X 0 0 0 Hatfield Judy Board Member 1 0 X 0 0 0 Hawley Bill Board Member 1 0 X 0 0 0 Henry Kim Board Member 1 0 X 0 0 0 Henry Robert Board Member 1 0 X 0 0 0 Hogan Randy Board Member 1 0 X 0 0 0 Holmes Jerome Board Member 1 0 X 0 0 0 Hudson Cliff Board Member 1 0 X 0 0 0 Jameson Brett Board Member 1 0 X 0 0 0 Johnstone Bill Board Member 1 0 X 0 0 0 Kerr Lou Board Member 1 0 X 0 0 0 Levy Harrison Board Member 1 0 X 0 0 0 Little Dan Board Member 1 0 X 0 0 0 Loughridge Bill Board Member 1 0 X 0 0 0 Mahaney Mindy Board Member 1 0 X 0 0 0 McCarty Jack Board Member 1 0 X 0 0 0 Morris Jim Board Member 1 0 X 0 0 0 Mueller James Board Member 1 0 X 0 0 0 Nichols Larry Board Member 1 0 X 0 0 0 Parry Richard Board Member 1 0 X 0 0 0 Patten Rebecca Board Member 1 0 X 0 0 0 Payne Bond Board Member 1 0 X 0 0 0 Pierson Gary Board Member 1 0 X 0 0 0 Pitman Don Board Member 1 0 X 0 0 0 Rainbolt David Board Member 1 0 X 0 0 0 Replogle Dee Board Member 1 0 X 0 0 0 Rooney Pat Board Member 1 0 X 0 0 0 Ross Bob Board Member 1 0 X 0 0 0 Samis Mike Board Member 1 0 X 0 0 0 Saxon John Board Member 1 0 X 0 0 0 Schulte Paul Board Member 1 0 X 0 0 0 Stough Phyllis Board Member 1 0 X 0 0 0 Swimmer Ross Board Member 1 0 X 0 0 0 Switzer Becky Board Member 1 0 X 0 0 0 Taylor Steven Board Member 1 0 X 0 0 0 Thorpe Betsy Board Member 1 0 X 0 0 0 Walton Greg Board Member 1 0 X 0 0 0 Williams Jr G Rainey Board Member 1 0 X 0 0 0 Wymer Deane Board Member 1 0 X 0 0 0 Prescott Stephen President and CEO 50 0 X 1061395 0 242459 Paul Kincade VP of Research & Member, Immunobiology and Cancer 50 0 X 221192 0 27570 Morgan Chip Executive VP & Chief Operating Officer 50 0 X 232627 0 35864 Cohen Adam Sr VP & General Counsel 50 0 X 232451 0 40124 Voss Penny VP of Development 50 0 X 204840 0 60143 Nair Manu VP of Technology Transfer 50 0 X 190482 0 33604 Hassen Tim VP and CFO 50 0 X 216416 0 46901 Day Lisa VP of Business and Government Affairs 50 0 X 115462 0 26178 Courtney Stevens VP of Human Resources 50 0 X 144443 0 25590 James Judith Program Chair, Arthritis and Clinical Immunology 50 0 X 385537 0 51294 McEver Rodger Program Chair, Cardiovascular Biology 50 0 X 289162 0 30627 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 50 0 X 333783 0 36303 Jones David Program Chair, Functional and Chemical Genomics 50 0 X 306758 0 42601 Gaffney Patrick Member, Arthritis and Clinical Immunology 50 0 X 272134 0 52975 Sivils Kathy Member, Arthiritis and Clinical Immunology 50 0 X 233152 0 41751 Nath Swapan Member, Arthritis and Clinical Immunology 50 0 X 221132 0 42052 4660966 0 836036 59 0 1 0 Infusion Management LLC 11233 Shadow Creek Pkwy Pearland TX 77584 Medical Billing Services 6581499 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 513904 Parker Highlander 1120 S Capital of Texas Hwy Bldg One Ste 200 Austin TX 78746 Legal 150131 3 127094 0 0 0 36924325 18397347 296743 55448766 Clinic Revenue 621399 9728825 9728825 0 0 0 0 0 0 9728825 3818660 3818660 0 0 98735 98735 0 0 2289103 2289103 0 0 445084 0 0 0 445084 0 445084 445084 0 0 301274 247531 302586 1505036 -1312 -1257505 -1258817 -1258817 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Cafe Income 722100 287716 287716 0 0 Laboratory Income 541380 1514576 1514576 0 0 0 0 0 0 1802292 72372648 16923882 0 0 3498849 2470432 823577 204840 0 23143617 21263417 922034 958166 7880290 6994165 545014 341111 147745 101290 46455 0 89100 61085 28015 0 567178 0 567178 0 1101848 1101848 0 0 583067 333655 81358 168054 897897 748370 102283 47244 3387595 2634398 753004 193 566322 479803 41429 45090 49864 45065 1877 2922 2530642 2446821 83821 0 7926109 7539524 386585 0 336669 230812 105857 0 Lab supplies 4003501 4003501 0 0 Trainee costs 1091245 1091245 0 0 Inhouse 1253356 1208281 29815 15260 Subcontracts 12625748 12625748 0 0 1462581 1249510 2907 210164 73143223 66628970 4521209 1993044 5100 5100 21660063 27129840 9834071 7414994 2129623 2572360 0 0 0 0 215589 192000 4815 6968 444802 381912 225920808 117171707 114879157 108749101 105455082 102596301 2170938 2169004 0 0 0 0 135697443 128110014 392496683 379327594 6580381 8380117 0 0 0 0 49883269 48783096 0 0 0 0 0 0 0 0 4337814 5859809 60801464 63023022 X 107390595 105600945 37606428 32525207 186698196 178178420 331695219 316304572 392496683 379327594 X -770575 -5311983 0 0 0 -9308089 X 0 1 X 1 1 1 X 56883620 51804565 55978368 51927440 55448766 272042759 0 0 0 0 0 0 0 0 0 0 0 0 56883620 51804565 55978368 51927440 55448766 272042759 44256154 227786605 6055949 6515711 7714644 7176342 7195057 34657703 0 0 0 0 0 0 0 0 0 0 0 0 306700462 9728825 0.74270 0.75694 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 567178 0 0 567178 0 Schedule C, Part II-B, Line 1 The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 86604791 389217 -1175973 0 3800000 0 82018035 86302560 1057014 2745217 0 3500000 0 86604791 76260090 390308 12952162 0 3300000 0 86302560 66735078 3205030 9519982 0 3200000 0 76260090 69793689 76613 64776 0 3200000 0 66735078 0.054 0.668 0.278 1 0 3944520 0 3944520 180316326 0 84526917 95789409 0 0 0 0 41634366 0 32644790 8989576 25596 0 0 25596 108749101 Funds Held in Trust by Others 122881870 Wills and Bequests 2773122 Cash Surrender Value of Life Insurance 1721482 Debt Issue Costs 326394 Deposits 87288 Accrued Interest Receivable 110605 Assets Held for Sale 209146 Minerals 107 128110014 Split Interest Agreements & Other Liabilities 668280 Postretirement Benefits & Deferred Compensation 5191529 5859809 X 57752576 -5311983 0 0 -9308089 -14620072 72372648 0 0 0 72372648 73143223 0 0 0 0 0 73143223 0 0 0 73143223 Schedule D, Part V, Line 4 The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 Management has reviewed the Foundation's tax positions and concluded that there are no uncertain tax positions that require accrual in the financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2013. Schedule D, Part XI, Line 2d Includes change in fair value of funds held in trust by others as well as pension related changes other than net periodic pension costs. X 1 1 X X X X X X 0 1 0 0 0 0 0 1 0 Prescott Stephen President and CEO 787313 0 235504 0 38579 0 223056 0 10441 0 1294893 0 0 0 Paul Kincade VP of Research & Member, Immunobiology and Cancer 174877 0 21249 0 25067 0 17468 0 10103 0 248764 0 0 0 Morgan Chip Executive VP & Chief Operating Officer 205340 0 375 0 26912 0 25323 0 10541 0 268491 0 0 0 Cohen Adam Sr VP & General Counsel 194031 0 200 0 38220 0 31035 0 9089 0 272575 0 0 0 Voss Penny VP of Development 184908 0 0 0 19932 0 44107 0 16036 0 264983 0 0 0 Nair Manu VP of Technology Transfer 189102 0 0 0 1380 0 20935 0 12669 0 224086 0 0 0 Hassen Tim VP and CFO 208576 0 100 0 7740 0 31015 0 15886 0 263317 0 0 0 Day Lisa VP of Business and Government Affairs 111081 0 0 0 4381 0 10344 0 15834 0 141640 0 0 0 Courtney Stevens VP of Human Resources 141987 0 200 0 2256 0 14594 0 10997 0 170034 0 0 0 James Judith Program Chair, Arthritis and Clinical Immunology 339102 0 10000 0 36436 0 41486 0 9809 0 436833 0 0 0 McEver Rodger Program Chair, Cardiovascular Biology 244994 0 0 0 44168 0 25353 0 5274 0 319789 0 0 0 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 332931 0 0 0 852 0 26612 0 9691 0 370086 0 0 0 Jones David Program Chair, Functional and Chemical Genomics 305910 0 50 0 798 0 26766 0 15836 0 349360 0 0 0 Gaffney Patrick Member, Arthritis and Clinical Immunology 257722 0 0 0 14412 0 37118 0 15857 0 325109 0 0 0 Sivils Kathy Member, Arthiritis and Clinical Immunology 231460 0 0 0 1692 0 25174 0 16577 0 274903 0 0 0 Nath Swapan Member, Arthritis and Clinical Immunology 201320 0 0 0 19812 0 25497 0 16556 0 263185 0 0 0 Schedule J, Part I, Line 1a First class travel is allowed for the CEO to allow him to accomplish work related tasks while traveling. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. Schedule J, Part I, Line 4 The Board of the Foundation periodically uses nonqualified retirement plans as a retention tool. Schedule J, Part I, Line 7 The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. A Oklahoma Industries Authority 736194355 679103YC9 2008-08-14 42955000 Revenue Bonds (OMRF Project) Series 2008 0 0 0 B Oklahoma Industries Authority 736194355 XXNONEXXX 2010-05-26 12185000 Revenue Bonds (OMRF Project) Series 2010 0 0 0 A 7180000 0 43457720 3316750 0 0 141976 0 0 30540129 0 9418857 2011 0 0 0 1 B 0 0 12320300 1218339 0 0 138825 0 0 0 10963136 0 2011 0 1 1 1 A 0 0 0 1 1 0 0 0 1 0 1 B 0 0 0 1 1 0 0 0 1 0 1 A 0 0 0 1 0 0 0 1 1 B 1 0 0 0 0 1 A 1 B 1 Schedule K, Part IV, Line 2c-08/14/2008 42,955,000 Oklahoma Industries Authority No rebate was due according to the rebate calculated November 21, 2013 for the rebate period beginning May 26, 2010 through June 30, 2013. Accele Venture Partners Common Directors 173949 Equity Investment 0 Accele Biopharm Common Directors 100000 Equity Investment 0 Bank of Oklahoma Common Directors 119977 Investment and mineral asset management 0 X 13 296743 FMV 0 0 1 1 Schedule M, Part I, Line 32b A third party is used to sell gifts of stocks or bonds received from donors. Usually the donor transfers the stocks directly from their brokerage account into OMRF's third party account. Occasionally, OMRF receives stock certificates and those are sent directly to the third party to process. Form 990, Part VI, Section A, Line 1a The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Section A, Line 2 The Foundation currently has 83 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Form 990, Part VI, Section B, Line 11b A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Section B, Line 12c Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Section B, Line 15 Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Section C, Line 19 The Foundation's governing documents, conflicts of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Includes change in fair value of funds held in trust by others as well as pension related changes other than net periodic pension costs.